Objectives: To determine the outcome of patients with a serum prostate-specific antigen (PSA) level 420 ng/ml that underwent radical prostatectomy (RP). Methods: We retrospectively reviewed the medical records of 147 patients who underwent RP for clinically localized prostate cancer with a pre-treatment PSA (PSApt) 420 ng/ml. Fifty-two patients had positive pelvic lymph nodes and were excluded from analysis. Of 95 patients remaining, 15 were lost to follow-up. Therefore, the study group included 80 patients. The end points for this analysis were biochemical relapse-free survival (bRFS), surgical and post-operative complications and urinary continence. PSApt, pathological grade, surgical margin status, age, clinical stage and immediate androgen ablation were evaluated in a multivariate analysis regarding bRFS. Results: Forty-nine resected specimens (61.2%) were pathologically classified as pT3 or pT4. After a mean follow-up of 64 months, the estimated 5-year bRFS rate was 58% for the overall group. Immediate androgen ablation was the only independent prognostic factor for biochemical relapse (P ¼ 0.001). Concerning the 21 patients who received an immediate androgen ablation after RP, the estimated 5-year bRFS rate was 92%. Complete urinary continence was achieved in 76.5% of patients. Early complications occurred in 13 patients (16.2%). Conclusions: Clinically localized prostate cancer with a PSApt 420 ng/ml is considered as having a poor prognosis. However, RP performed in these patients led to an acceptable morbidity and good functional results. Immediate adjuvant hormonal therapy seems mandatory in this setting to improve bRFS.
Introduction
Pre-treatment prostate-specific antigen (PSA) level (PSApt) is an independent prognostic factor for prediction of capsular perforation, seminal vesicle invasion, positive surgical margins and nodal metastases.
1,2 High pre-treatment PSA (PSApt) levels are considered as poor prognostic factor for biochemical relapse after radical prostatectomy (RP). Several studies reported that PSApt is a significant clinical predictor of post-operative biochemical relapse. 2, 3 According to D'Amico et al., 4 patients with a PSApt of greater than 20 ng/ml at diagnosis are at high risk for death from prostate cancer after external beam radiation therapy. D'Amico et al. 5 has proposed pre-treatment risk groups for predicting biochemical relapse after local therapy. High-risk group is defined by PSApt 420 or biopsy Gleason score 47 or clinical stage T2c (Tumor Node Metastasis (TNM) 1992). For this group, the probability of 5-years PSA failure-free survival rate is approximately 40%. Owing to the concern for micrometastatic disease and locally advanced disease, surgical therapy for men with markedly elevated PSA levels is controversial and traditionally not considered a routine treatment option. Owing to the higher incidence of positive surgical margins and presumed recurrence, an adjuvant therapy associated with local treatment has been advocated by several authors. [6] [7] [8] [9] This study aimed to evaluate the relapse-free survival (RFS) rate and possible predictors of favourable outcome as well as morbidity and continence rates in patients that underwent RP with PSApt 420 ng/ml in a single institution.
Patients and methods

Patient population and inclusion criteria
Between 1991 and 2002, a total of 147 patients with biopsy proven clinically localized prostate cancer and PSApt 420 ng/ml underwent radical retropubic prostatectomy along with bilateral pelvic node dissection at our institution. Pre-operative staging included history and physical examination, serum PSA, transrectal ultrasound-guided needle biopsy of the prostate with World Health Organization (WHO) histologic grading, chest Xray, radioisotopic bone scan and pelvic-abdominal tomodensitometry. The local tumour stage was determined from the digital rectal examination (DRE) and transrectal ultrasound. Patients were considered for RP when no evidence of distant metastatic disease was suspected.
Fifty-two patients (35.3%) who were found to have positive pelvic lymph nodes at the time of frozen section or at final pathologic evaluation were excluded from the study. Of the remaining 95 patients, 15 were lost to follow-up and therefore excluded from analysis. Of 80 study patients, two received neoadjuvant androgen ablation before prostatectomy, based on Luteinizing Hormone-Releasing Hormone agonist (LHRH agonist) for 1 month. Twenty-one patients (26.2%) underwent immediate adjuvant androgen ablation therapy, by orchiectomy in 17 patients and LHRH agonist application in four patients (42 years). Indications for immediate adjuvant androgen ablation were post-operative detectable PSA for 13 patients and unfavourable pathologic findings for eight patients.
Patients clinical and pathological characteristics
Both clinical and pathological stagings were assessed according the 1997 TNM system. Table 1 summarizes the pre-operative clinical characteristics for the 80 study patients.
The median serum PSApt was 29.5 (20.3-162) ng/ml. The mean age of patients was 64.8 (52-77) years. The histopathologic grade of tumours was established according to the WHO and discriminated into well, moderately and poorly differentiated tumours, respectively. Unfortunately, the Gleason score was available for only a minority of patients.
Continence
Post-operative urinary continence was assessed according to the criteria of the International Continence Society (ICS) and was divided into four categories. Patients were considered to be continent if no involuntary urine loss occurred during normal or strenuous activities and no pads or appliances were needed at any time. Patients with occasional spotting of urine in the underwear on coughing or sneezing or strenuous activities were considered to have stress incontinence grade 1. Stress incontinence grade 2 included frequent loss of urine during normal activities, such as walking or climbing stairs, and wearing sanitary pads for protection. No urinary control, neither in an upright nor in a supine position, was considered to be stress incontinence grade 3. Continence data were obtained by questionnaires, which were mailed to the referring urologist or to the house physician, and the patients filled out all questionnaires.
Follow-up
The mean follow-up after surgery was 64 (13-168) months. Patients were followed every 3 months during the first 2 years, every 6 months until year 5 and annually thereafter. PSA levels were measured at each visit and DRE was performed annually. Imaging studies were obtained when either biochemical or clinical evidence of disease recurrence was evident.
All data were collected prospectively in an institutional computer database. The follow-up parameters were continence, biochemical progression and clinical progression. Time to progression was defined as time from surgery to the date of biochemical or clinical progression. A detectable PSA level (0.2 ng/ml or greater) at 6 weeks post-operatively was defined as persistent PSA and two serial detectable PSA levels after reaching the nadir or non-detectable level was defined as PSA progression. 10 
Analysis
The end points for analysis were biochemical RFS (bRFS), complications and continence. Cox proportional hazard regression (stepwise analysis) was used to determine independent prognostic factors of biochemical relapse. A P-value less than 0.05 was considered significant. Prognostic factors analysed were: clinical stage (T1 vs T2), pre-treatment PSA (p30 vs 430), histological grade (G1/G2 vs G3), surgical margin status (0 vs X1), age (p65 vs 465) and immediate androgen ablation (yes vs no). We have chosen median PSA value (30 ng/ml) for analysis because no significant cutoff value was observed with ROC curve analysis. Owing to the small number of events (death owing to prostate cancer and metastasis), no analysis was attempted in regard of cancer-specific and metastasis-free survival.
Results
Pathological findings
Pathological characteristics are summarized in Table 2 . Of 80 patients, 31 had pathologically organ-confined tumours. Forty-seven patients (58.8%) had positive surgical margins, but only 11 (13.8%) had more than one margin involved. Concerning the WHO specimen grade, the majority (65%) was grade 2. Role of radical prostatectomy in patient C Bastide et al
Adjuvant therapy
At the time of analysis, 46 patients (57.5%) had not received any adjuvant therapy. Among these 46 patients, 19 (23.8%) were alive and without evidence of disease and six (7.5%) patients had died without evidence of disease. Twenty-one patients (26.3%) have received immediate androgen ablation (orchiectomy or LHRH agonist) after RP. Thirteen patients (16.3%) underwent androgen ablation and/or radiotherapy after RP owing to a post-operative detectable PSA or biochemical or clinical disease progression. Of the five patients treated by adjuvant radiotherapy, four patients presented isolated local recurrence. Five patients received more than one form of adjuvant therapy (Table 3) .
Disease progression and survival
After a mean follow-up of 64 (13-168) months from RP, 40 patients (50%) were alive without disease progression, 22 patients (27.5%) were alive with biochemical failure, eight (10%) were alive with clinical signs of progression and 10 (12.5%) patients have died. Of the 10 patients who died during follow-up, three (3.7%) have died of prostate cancer and seven (8.7%) died owing to other causes. Only one of these seven patients presented biochemical relapse without detectable clinical progression. At median follow-up of 52733.2 months, recurrence was observed in 36 patients (45%) including 25 with biochemical relapse only (between 2 and 120 months after prostatectomy); four patients with isolated local recurrence (between 16 and 34 months after prostatectomy) and seven patients with distant metastases (between 19 and 109 months after prostatectomy). None had local or distant recurrence without an increase in PSA at the time of progression. For the overall group (Figure 1) , the estimated 5-year bRFS rate was 58% (standard error: 0.078). At the time of analysis, 19 patients (23.8%) were alive and biochemical disease free after RP alone (mean follow-up 51 months).
Concerning the 21 patients who received immediate androgen ablation after RP, 18 were alive without biochemical disease progression (86%) at a median follow-up of 89 months, one patient died of prostate cancer, one patient died without biochemical relapse and one patient presented a clinical progression. For this subgroup, the estimated 5-year bRFS rate was 92% (standard error: 0.053).
Concerning the 59 patients who did not receive immediate androgen ablation after RP, the estimated 5-year bRFS was 33% (standard error: 0.074).
Neither PSApt nor age, clinical stage, margin status and pathological grade were significant predictors of biochemical relapse after RP. Only immediate androgen ablation (yes vs no) was an independent prognostic factor of biochemical relapse (P ¼ 0.001) after RP (Figure 2 ).
Complications
Complications related to RP were categorized as intraoperative, early post-operative (less than 6 weeks after surgery) and late post-operative (more than 6 weeks after surgery).
Intraoperative complications occurred in only one patient (1.3%) with a rectal injury (primary closure, no stoma). There was no operative or perioperative death. Early post-operative complications occurred in 13 patients (16.2%), comprising one complication in 11 (13.7%) and two complications in two (2.5%) patients. The main complications were superficial wound infections and lymphoceles. Early post-operative complications are Role of radical prostatectomy in patient C Bastide et al summarized in Table 4 . Late complications occurred in six patients (7.5%). Strictures of the urethral anastomosis requiring endoscopic incision developed in five patients (6.2%), and one patient (1.3%) developed a stricture of the distal urethra requiring urethrotomy.
Continence
Post-operative urinary continence was analysed at 1, 2 and 3 years follow-up and are listed in Table 5 . At 1 year post-operatively, 85% of patients were either completely continent or reported occasional spotting, causing no considerable discomfort (grade 1). Further improvement with a rate of total continence of 57.5 (at 1 year followup) to 76.5% (at 3 years follow-up) was observed, which was predominantly owing to the fact that patients with grade 1 urinary incontinence regained complete urinary control. The rate of grade 2 urinary incontinence decreased from 13.7% at 1 year to 8.8% at 3 years follow-up. The rate of unsatisfactory urinary incontinence (grade 3) remained very low after 1 year of followup (one out of 80 patients).
Discussion
Complications In 1.3% (one patient), an injury of the rectum occurred, which was closed primarily and healed without further complications. No colostomy was required. As published previously, the rate for rectal lesions during RP varies between 0 and 3%. 11, 12 The rates of early complications following RP vary between 7 and 33% according to different studies. 13, 14 In our study, 15 early complications were observed and only two required surgical treatment. The main early complications were represented by lymphocele (6.3%) and wound infection (3.8%). The rates of these complications are reported in 0-6% in the literature. 11, 12 Late complications of RP (except incontinence and impotence) occurred in 7.5% (six patients), comprising anastomotic stricture in five and urethral stricture in one. This figure is similar to those reported in the literature, ranging from 1 to 13%.
11,12,15
Continence
In our series, post-operative urinary incontinence has been followed for 1 year or longer. At 1 year's follow-up, 85% were considered to be either completely continent (57.5%) or to experience occasional urine spotting (27.5%).
These patients with grade 1 stress incontinence have not been affected by this in their everyday activities. At 3 years follow-up, the total continence rate reached 76.5% of men (52 of 68), whereas 14.7% had grade 1 stress incontinence and only 8.8% had grade 2 stress incontinence. No patient was completely incontinent. We did not find that urinary continence was influenced by age or pathologic stage (data not showed).
The rates of urinary continence reported in the literature after RP vary between 75 and 93%. [15] [16] [17] Regarding both intraoperative and post-operative complications as well as continence, our results are similar to previous reports. RP performed in patients with PSApt 420 ng/ml leads to acceptable morbidity.
Surgical margins
In our study group, surgical margins were positive in 47 of 80 specimens (58.8%). Previous studies have clearly demonstrated a positive association between high initial PSA values and positive margins. Surgical margins involvement occurs in 46-69% of cases with PSApt 420 ng/ml. Role of radical prostatectomy in patient C Bastide et al
Pathologic stage
Our data showed that 38.8% of patients had pathologically organ-confined disease. These findings are in accord with previous series. In the literature, extracapsular extension (ECE) has been highly correlated with PSApt values. ECE rates of 50-85% have been reported in patients with PSApt 420 ng/ml. 2, 9, 18, 19, 21 However, in most studies, the rates reported were over 70%.
Biochemical relapse and prognostic factors
At the time of analysis, 45% of patients had a biochemical relapse. Between prognostic factors studied, only immediate androgen ablation was a significant predictor of biochemical relapse. No pre-operative factor was significant. For the overall group, estimated 5-year bRFS rate was 58%. This lower recurrence rate may be explained by two reasons. Firstly, 26.2% of patients received immediate androgen ablation.
Secondly, we have excluded from analysis patients who had positive pelvic lymph nodes. However, previous studies reported similar results.
Brandli et al. 19 reported a 5-year bRFS of 48% after RP in 50 patients (PSA level: 20-100 ng/ml) with 4% presenting positive lymph node. This lower recurrence rate may be explained by the low rates of positive margins (46%) and ECE (50%). They demonstrated that ECE only was predictive of PSA recurrence. In their study, no pre-operative factor was significant of biochemical relapse.
Likewise, Vanasupa et al. 21 observed a favourable bRFS after RP in 17 patients with PSApt 440 ng/ml and 18% presenting positive lymph node. They demonstrated a bRFS of 52.9% and 26.5% at 5 and 9 years respectively. However, many patients received neoadjuvant (29.5%) and/or early adjuvant therapy without biochemical failure (41%). Only two patients (12%) were cured from RP alone. In contrast, in our study 23.8% of patients are alive and biochemical disease free after RP alone.
In contrast, Kupelian et al. 9 reported a 5-year bRFS of 26% for T1-T2 cases with PSApt 420 ng/ml after RP in 48 patients. However, the rate of positive lymph node was 31%. A similar low 2-year bRFS of 24% was observed in 64 patients with PSApt 420 ng/ml after RP by D'Amico et al. 18 In a more recent study, D'Amico et al. 5 reported an estimated 2-and 10-year bRFS of 58 and 29%, respectively, after RP in 414 patients classified in the high-risk group (PSApt 420 ng/ml or biopsy Gleason score 47 or stage T2c). The difference observed between these D'Amico's studies is likely owing to group size and prognostic variations within the high-risk group.
In summary, the 5-year bRFS rates vary between 24 and 58% according to use or not of adjuvant therapy.
The issue of adjuvant therapy after RP in patients in the high-risk group has been raised many years ago. Zagars et al. 6 considers that a patient defined as having unfavourable disease (PSA 420 ng/ml) on the basis of pre-treatment PSA level, T category and Gleason's grade still has unfavourable disease even after his lymph nodes are shown to be negative on a standard pelvic lymphadenectomy. The Johns Hopkin's group also concluded that recurrence rates after RP for men in the high-risk group were similar to those men with positive pelvic lymph nodes. 7 That is why several authors have suggested the use of adjuvant therapy associated with local treatment in the high-risk group. [6] [7] [8] These findings are sustained by the results from the second analysis of the early prostate cancer programme. 22 For high-risk patients, the 5-year bRFS was significantly improved in the bicalutamide group in comparison with the placebo group.
Likewise, adjuvant radiotherapy seems very interesting after RP for high-risk patients. Recently, the European Organization for Research and Treatment of Cancer (EORTC) trial 22911 demonstrated a significant benefit of post-prostatectomy irradiation for preventing biochemical relapse in the high-risk group. 23 In agreement with this approach, we have observed in our series a surprising result with immediate adjuvant therapy (androgen ablation) after RP. At the time of analysis, among the 21 patients receiving an immediate adjuvant therapy after RP, the estimated 5-year bRFS rate was 92%. The estimated 5-year bRFS difference observed between patients treated by RP with immediate androgen ablation and patients treated by RP only was very significant (P ¼ 0.01).
It would be interesting to propose a randomized study to compare RP with immediate androgen ablation vs RP alone in patients with clinically localized prostate cancer and PSA 420 ng/ml.
Conclusion
Clinically localized prostate cancer with a PSApt 420 ng/ml represents a rarely studied group and is considered presenting a poor prognosis. Adjuvant hormonal therapy seems to improve the bRFS in this high-risk patients group. Unfortunately, no pre-treatment prognostic factors (clinical stage, tumour grade, PSA level) seem to be helpful for ultimate selection of candidates for RP.
